COOL: New Director Regains Nasdaq Listing Requirement
Apr 25, 2018 13:04:41 GMT
miamianne67 and c2crusher like this
Post by icemandios on Apr 25, 2018 13:04:41 GMT
PolarityTE, Inc. Regains Compliance With NASDAQ Independent Director Requirement
SALT LAKE CITY, April 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced it has received formal notification from the Listing Qualifications Department of The NASDAQ Stock Market ("NASDAQ") notifying PolarityTE that it has regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2), the independent director requirement for continued listing on The NASDAQ Stock Market, with the appointment of Mr. Willie Bogan, and that the matter is now closed. PolarityTE’s common stock will continue to be listed on The NASDAQ Capital Market.
On November 1, 2017, NASDAQ notified the Company that it did not comply with the independent director requirement for continued listing on The Nasdaq Capital Market set forth in Listing Rules 5605(b)(1) and 5605(c)(2). The Rule requires that a majority of the directors comprising the Company’s Board of Directors be considered “independent,” as defined under the Rule. On April 23, 2018, NASDAQ provided confirmation to the Company of the foregoing and that the Company has regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2).
About PolarityTE™
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient’s own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient’s own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient’s own tissue and uses the patient’s own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE’s innovative method is intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing.
SALT LAKE CITY, April 25, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced it has received formal notification from the Listing Qualifications Department of The NASDAQ Stock Market ("NASDAQ") notifying PolarityTE that it has regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2), the independent director requirement for continued listing on The NASDAQ Stock Market, with the appointment of Mr. Willie Bogan, and that the matter is now closed. PolarityTE’s common stock will continue to be listed on The NASDAQ Capital Market.
On November 1, 2017, NASDAQ notified the Company that it did not comply with the independent director requirement for continued listing on The Nasdaq Capital Market set forth in Listing Rules 5605(b)(1) and 5605(c)(2). The Rule requires that a majority of the directors comprising the Company’s Board of Directors be considered “independent,” as defined under the Rule. On April 23, 2018, NASDAQ provided confirmation to the Company of the foregoing and that the Company has regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2).
About PolarityTE™
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient’s own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient’s own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient’s own tissue and uses the patient’s own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE’s innovative method is intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing.